Among patients with focal treatment-resistant epilepsy, seizure frequency often decreases over time regardless of changes in medication or neuromodulation device use. The addition of antiseizure medications rarely achieves seizure freedom but frequently contributes to reductions in seizure burden. https://ja.ma/47jMFds
JAMA Neurology
Book and Periodical Publishing
Chicago, Illinois 28,434 followers
A member of the JAMA Network, which includes JAMA, 11 specialty journals, and JAMA Network Open.
About us
JAMA Neurology is an international peer-reviewed journal for physicians caring for people with neurologic disorders and those interested in the structure and function of the normal and diseased nervous system. JAMA Neurology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. S. Andrew Josephson, MD, Professor of Neurology and Chair of the Department of Neurology, University of California, San Francisco, is the editor in chief.
- Website
-
https://jamanetwork.com/journals/jamaneurology
External link for JAMA Neurology
- Industry
- Book and Periodical Publishing
- Company size
- 1,001-5,000 employees
- Headquarters
- Chicago, Illinois
- Founded
- 1919
- Specialties
- Neurology
Updates
-
Oseltamivir treatment during influenza episodes was associated with a reduced risk of serious neuropsychiatric events in children and adolescents enrolled in Tennessee Medicaid. https://ja.ma/43egtHc
-
Editorial: Recent trials of wearable nerve stimulators for essential tremor offer limited benefit over placebo. Noninvasive therapies may expand options for ET, but more evidence is needed before these devices achieve widespread uptake. https://ja.ma/3IS1oEA
-
-
Essential tremor (ET), the most common upper limb tremor, can impair daily activities. In a multicenter RCT, an artificial intelligence–driven transcutaneous peripheral nerve stimulation (TPNS) device reduced mADL scores by 6.9 points at 90 days, compared with a 2.7-point reduction in the sham group. https://ja.ma/46YcYqQ
-
-
JAMA Network is calling for submissions on #AI in medicine. We welcome rigorous studies on: • Clinical outcomes vs standard care • Real-world deployment of FDA-cleared AI tools • Efficiency gains for clinicians • Patient trust and equity • Evaluation of existing AI tools 🔗 Learn more about submission criteria: https://ja.ma/46TxbxW
-
-
Adding argatroban or eptifibatide to intravenous thrombolysis did not improve reperfusion rates or clinical outcomes in endovascular thrombectomy for acute ischemic stroke. https://ja.ma/495Idla
-
-
In women with multiple sclerosis, disease-modifying therapy management during pregnancy increased relapse risk, particularly in patients receiving natalizumab with prolonged interruption or fingolimod. https://ja.ma/46ZweEt
-
-
Editorial: Plasma p-tau217 is a promising yet complementary #Alzheimer biomarker, aiding diagnosis and trial efficiency but not fully replacing CSF and PET, especially in those without cognitive impairment. https://ja.ma/48tY1xU
-
-
Across the JAMA Network, we seek submission of manuscripts describing original research that examines the application of #AI in clinical settings. 🔗 Learn more about submission criteria: https://ja.ma/4nTsUkf
-
-
Using tau PET and plasma p-tau217 biomarkers may refine #Alzheimer trials by tracking disease progression in real-time and anticipating cognitive changes prior to impairment. https://ja.ma/4hhc50a
-